Strategic Partnerships Arctoris strengthens its sales potential through high-profile collaborations with leading academic institutions (University of Cambridge, King’s College London) and industry players (Intellomx, SpiroChem AG, Eli Lilly’s Life Sciences Studio). This suggests opportunities to position Ulysses as the automation backbone for joint drug discovery programs and cloud-based research collaborations.

AI-Driven Discovery Recent press highlights show Arctoris leveraging artificial intelligence to identify novel drug combinations and accelerate discovery. This indicates potential upsell to partners seeking AI-enabled target validation, combination therapies, and data-driven decision support on early-stage screening.

Cloud Lab Leadership For sales outreach, emphasize Arctoris’s recognition as a pioneer of cloud lab solutions in oncology research and its scalable, automated platform. This can resonate with biotechs aiming to de-risk lab operations, scale experiments, and move from pilot to full-scale programs.

Robotics and Data Arctoris’s value proposition centers on robotic automation and high-quality datasets. Position offerings to potential customers needing reproducible data, rapid iteration, and integrated data science for assay cascades from target to candidate, appealing to firms with complex discovery pipelines.

Expansion and Capacity Ongoing laboratory expansion in Oxford indicates capacity growth and longer-term engagement potential. Target companies seeking reliable CRO capacity to support expanding discovery programs, with cross-border collaboration and integrated workflows around Ulysses.